CHNC China Infrastructure Construct

Cannabis Bioscience International Holdings Announces the Appointment of Former Dallas Cowboy David Irving as Spokesperson of Our Company

Cannabis Bioscience International Holdings Announces the Appointment of Former Dallas Cowboy David Irving as Spokesperson of Our Company

HOUSTON, TX, April 17, 2023 (GLOBE NEWSWIRE) -- via -- CBIH, previously known as CHNC, and trading under the ticker symbol CHNC, has the pleasure to announce former football player, David Irving, as its new spokesperson.

The commitment and devotion of Mr. Irving to the game of football has not only been remarkable but a game changer. Moreover, one of the exceptional determinations he’s had during his career is to advocate for cannabis use in sports. Following his suspension after testing positive for a drug test, he has publicly reached out to the NFL to change outdated policies and the collective bargaining agreement (CBA). The outcome was the reduction of the testing window and the eradication of suspensions for NFL players.

In addition, as a patient, he’s been vocal about the medical use of cannabis and its benefits in treating his anxiety, sleep, and pain management due to the multiple injuries he’s suffered throughout his career. As a result, he has repelled the stigma surrounding the plant and its use in the professional sports field while acknowledging and expressing the severe and long-term side effects of available treatments, such as opioids, that are widely accepted in medical and athletic practice.

As a former four year-player for the Dallas Cowboys, and as a triumphant playmaker with the Las Vegas Raiders he was able to convey a clear and sound statement that cannabis goes beyond smoking and also encapsulates the palliative properties for a better quality of life. In addition, he also taught us that it's about awareness, better policies, justice, and, most of all, education.

“We welcome Mr. Irving with open arms, trusting that his experience will boost CBIH to the next level as we continue to develop our company’s great success,” says Henry Levinski, Vice President/Treasurer of CBIH. “He has taken risks bigger than anyone can imagine when trying to reach his goals and has encountered a favorable outcome in the process,” he adds.

With this trajectory, our company is thrilled to have acquired an alliance with Mr. Irving as CBIH´s Spokesperson. We believe his allegiance, passion, and hard work align with our company’s values and vision. Therefore, reinforcing our commitment to science, education, and medicine while continuing to attempt to upgrade and update the current legal frame and provide better opportunities for patients, caretakers, cannabis users, and professionals about the medical and industrial uses of the plant.

Thank you, Mr. Irving, for continuing to bring hope to new generations in the medical cannabis space. Gratitude for your best touchdown ever!

To learn more visit:

For more information contact us at:

817/528-2475 for English

214/733-0868 for Spanish

911/1121798903 for Italian

962/796269233 for Arabic

55/11966497868 for Portuguese



EN
17/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on China Infrastructure Construct

 PRESS RELEASE

CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 ...

Houston, Texas--(Newsfile Corp. - January 21, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today that it is in the evaluation stage of a potential financing transaction under Regulation A (Reg A), in an estimated amount in the order of $1,000,000, subject to change, internal review, and applicable market and compliance conditions.CBIH clarifies that this communication reflects a serious corporate and executive planning approach intended to protect business value and accelerate operati...

 PRESS RELEASE

CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr....

Houston, Texas--(Newsfile Corp. - January 12, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today the launch of its Evidence Sprint 2026, an intensive execution phase designed to turn cannabinoid science into usable medical evidence: protocols, operational collaboration, and projects ready for competitive funding.CBIH confirms receipt of a communication from the Centers for Medicare & Medicaid Services (CMS) acknowledging Company's meeting request with CMS Administrator Dr. Mehmet Oz a...

 PRESS RELEASE

CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accele...

Houston, Texas--(Newsfile Corp. - January 5, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the launch of a national outreach and partnership initiative designed to capitalize on the accelerating federal momentum toward moving cannabis from Schedule I to Schedule III through the ongoing rescheduling rulemaking process. On December 18, 2025, a Presidential Executive Order directed the U.S. Attorney General to take necessary steps to complete the rulemaking process related to resche...

 PRESS RELEASE

CBIH Announces New Patent Initiative Targeting Opioid Addiction Throug...

Houston, Texas--(Newsfile Corp. - December 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that it is pursuing a new patent for an investigational therapy designed to address opioid addiction, a condition that continues to claim tens of thousands of lives each year in the United States.According to U.S. public health data, more than 700,000 people have died from opioid-involved overdoses since the early 2000s. Despite recent progress, the crisis remains severe: in 2024 alone, a...

 PRESS RELEASE

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Op...

Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces a landmark corporate and industry moment following recent indications that President Donald Trump will support federal actions that advance the rescheduling of marijuana from Schedule I to Schedule III. The development is widely regarded as one of the most consequential policy shifts in nearly two decades of national debate.After eighteen years of navigating scientific challenges, market volatility, stigma, and regulatory uncertainty, CBIH stated that this turn...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch